Results 41 to 50 of about 134,715 (210)

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level. Methods Data of a prospective
Judith Berres, Justyna Wozniak, Hannah Fölsch, Anja Knueppel‐Ruppert, Verena Graeff, Andrea Kriegisch‐Stumpf, Harald Dormann, Julia C. Stingl, Katja S. Just   +8 more
wiley   +1 more source

Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions

Therapeutics and Clinical Risk Management, 2015
Yolande B Saab,1 Rony Zeenny,2 Wijdan H Ramadan2 1School of Pharmacy, Pharmaceutical Sciences Department, 2School of Pharmacy, Pharmacy Practice Department, Lebanese American University, Byblos, Lebanon Purpose: Response to clopidogrel varies widely with
Saab YB, Zeenny R, Ramadan WH
doaj  

Effect of obesity and serum leptin level on clopidogrel resistance

Türk Kardiyoloji Derneği Arşivi, 2016
Objective: Clopidogrel inhibits platelet aggregation by blockade of platelet adenosine diphosphate (ADP) P2Y12 receptor. Leptin is the obesity gene product, and its serum level increases with obesity.
Ali Dogan, Serkan Kahraman, Emrah Usta, Emrah Ozdemir, Uzay Gormus, Cavlan Ciftci   +5 more
doaj   +1 more source

Consistency and clarity of pharmacogenomic guidance in UK medicine patient information leaflets: A cross‐sectional analysis

British Journal of Clinical Pharmacology, EarlyView.
Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK‐approved medicines with strong evidence supporting a PGx ...
Parth Narlawar, Chloe Ratcliffe, Videha Sharma, William G. Newman, Munir Pirmohamed, John McDermott   +5 more
wiley   +1 more source

Population pharmacokinetic‐pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study

CPT: Pharmacometrics & Systems Pharmacology
Clopidogrel is an antiplatelet drug used to reduce the risk of acute coronary syndrome and stroke. It is converted by CYP2C19 to its active metabolite; therefore, poor metabolizers (PMs) of CYP2C19 exhibit diminished antiplatelet effects.
Yun Seob Jung, Byung Hak Jin, Min Soo Park, Choon Ok Kim, Dongwoo Chae   +4 more
doaj   +1 more source

The interplay between molecular architecture, pharmacology, and suspected adverse drug reactions associated with nonsteroidal androgen antagonists in the United Kingdom

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to correlate potential links between the suspected adverse drug reaction (ADR) profile of licensed nonsteroidal androgen receptor antagonists (NSARA) with their unique chemical properties and known off‐target polypharmacology. Methods Physicochemical and polypharmacology data were curated from the Electronic Medicines Compendium ...
Simrit Dhillon, Albert A. Antolin, Alan M. Jones   +2 more
wiley   +1 more source

The effect of doubling the dose of clopidogrel on platelet aggregation in patients with clopidogrel resistance

The Egyptian Heart Journal, 2014
Antiplatelet drugs play a pivotal role in the management of patients with acute coronary syndrome. Clopidogrel is an important antiplatelet drug commonly used in the treatment of those patients. However, the variability in patient response to clopidogrel
John I. Louca, George S. Mina, Bassem W. Habib, Sameh E. Sadek   +3 more
doaj   +1 more source

Radial capacity and hemodynamics evaluation in vitro and implantable feasibility validation in vivo of thinner bioresorbable polymer vascular stents

BMEMat, EarlyView.
A series of in vitro experiments, numerical simulations and in vivo experiments were conducted to jointly evaluate the effects of different thicknesses of bioabsorbable polymer vascular stents on their radial capacity, hemodynamics and in vivo outcomes.
Chong Chen, Tao Li, Zhongyou Li, Jingyuan Zhou, Zhuo Zhang, Yan Xiong, Rifang Luo, Yu Chen, Yunbing Wang, Ping Fu   +9 more
wiley   +1 more source

The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics

Cardiology Research and Practice, 2017
Dual antiplatelet therapy of aspirin and clopidogrel is pivotal for patients undergoing percutaneous coronary intervention. However, the variable platelets reactivity response to clopidogrel may lead to outcome failure and recurrence of cardiovascular ...
Arwa M. Amin, Lim Sheau Chin, Dzul Azri Mohamed Noor, Muhamad Ali SK Abdul Kader, Yuen Kah Hay, Baharudin Ibrahim   +5 more
doaj   +1 more source

The Prognostic Impact of Multiple Adverse Events on Long‐Term Mortality Following Acute Myocardial Infarction

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Adverse events after acute myocardial infarction (AMI) are individually associated with poor outcomes, but the prognostic impact of the overlap of different event types occurring sequentially within the same patient remains uncertain.
Kyung Hoon Roh, Yong Hee Kim, Eun Ho Choo, Kwan Yong Lee, Ik Jun Choi, Jong‐Min Lee, Ki‐Dong Yoo, Mahn‐Won Park, Chul Soo Park, Hee‐Yeol Kim, Min Chul Kim, Youngkeun Ahn, Kiyuk Chang   +12 more
wiley   +1 more source